Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

NCT03595566 - Ridinilazole vs Vancomycin & Clostridioides difficile infection (CDI) (initial)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Background

Exposure to antibiotics can lead to dysbiosis and Clostridioides difficile infection (CDI), which may become severe, recurrent (rCDI), and potentially life-threatening. The use of nonselective drugs to treat CDI can further contribute to dysbiosis and is linked to rCDI. This is partly because these treatments result in the loss of microbiome-derived secondary bile acid (SBA) production
Okhuysen et al. 2024 Clinical Infectious Diseases 78(6): 1462-1472

Study overview

NCT03595566 - Ridinilazole vs Vancomycin & Clostridioides difficile infection (CDI) (initial) is a double-blind, randomized clin…

References (Sources)

A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response
Okhuysen et al. 2024 Clinical Infectious Diseases 78(6): 1462-1472

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!